Navigation Links
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
Date:1/31/2008

applicable securities laws in Canada, (collectively referred to as "forward-looking statements"). Statements, other than statements of historical fact, are forward-looking statements and include, without limitation, statements regarding our strategy, future operations, timing and completion of clinical trials, prospects, plans and objectives of management. The words "anticipates", "believes", "budgets", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "projects", "schedule", "should", "will", "would" and similar expressions are often intended to identify forward-looking statements, which include underlying assumptions, although not all forward-looking statements contain these identifying words. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other things contemplated by the forward-looking statements will not occur.

Although our management believes that the expectations represented by such forward-looking statements are reasonable, there is significant risk that the forward-looking statements may not be achieved, and the underlying assumptions thereto will not prove to be accurate. Forward-looking statements in this news release include, but are not limited to, statements concerning our expectations for: increasing the celgosivir dose to 600mg being an important development step for the optimization and advancement of celgosivir; our plans to add approximately six patients at 600mg dose in the celgosivir Phase II viral kinetics study and having results from the study in the third quarter 2008; Cadence Pharmaceuticals completing enrollment in the CLIRS trial in the second quarter of 2008, with results available in the second half of 2008; and Cutanea Life Sciences' plans to advance omiganan for the treatment of rosacea to Phase III clinical developme
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
2. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
11. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Lyme Research Alliance (LRA), the nation’s ... universities, today announced the awarding of seven grants worth ... cure for Lyme and other tick-borne diseases. , ... its history—over 20 grant proposals—a 100 percent increase from ... receive so many solid applications from talented scientists this ...
(Date:9/30/2014)... September 30, 2014 Rainbow Scientific, ... research products, recently opened an online store to ... culture product lines developed and manufactured by Biological ... store include Biological Industries’ Nutristem® serum-free, xeno-free reagents ... embryonic stem cell (hESC) culture. , The ...
(Date:9/30/2014)... 2014 UFP Technologies, a producer ... has recently introduced a custom insulated shipping container ... The new insulated shipper solves the issue of ... UFP Technologies’ BioShell is a universal storage container ... handling and shipping. The insulated shipper keeps frozen ...
(Date:9/30/2014)... Canada (PRWEB) September 30, 2014 Back in ... on 500 square feet. per employee, which included space for ... back then.” says Jeff Howell, partner at Nidea Corporate ... firm in Toronto. “By the year 2000, however, 250 ... now seeing that number come down to 175 to 225 ...
Breaking Biology Technology:Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3
... Alba Therapeutics Corporation today,announced that its Investigational ... of endogenous insulin production capacity in new-onset,type 1 ... deliberation period,by the U.S. Food and Drug Administration ... study in 2008 while focusing the majority,of its ...
... will review common U.S. laws on research and process labs ... offer practical ... in association with Lab Manager Magazine, will present a Web,conference ... EST. The online conference will review common U.S. federal laws,pertaining ...
... SAN CARLOS, Calif., Sept. 5 NeurogesX, Inc.,(Nasdaq: ... developing novel,pain management therapies, announced today the appointment ... directors. Since May 2006, Mr. Peacock,has been a ... Prior to joining SV Life Sciences, Mr. Peacock ...
Cached Biology Technology:Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001 2Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 2Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 3NeurogesX Appoints New Director to the Board 2NeurogesX Appoints New Director to the Board 3
(Date:9/29/2014)... Energy Joint Genome Institute (DOE JGI), a DOE ... 32 new projects have been selected for the ... lakes to Caribbean waters, and from plant root ... in forested watersheds, the CSP 2015 projects portfolio ... be extracted. , "These projects catalyze JGI,s ...
(Date:9/29/2014)... anti-tumour activity in patients with advanced BRAF V600E ... progressed after chemotherapy, according to phase II data ... Spain. , "Reports of lung cancers bearing ... these mutations may be associated with increased sensitivity ... Dr David Planchard, pulmonary oncologist at the Gustav-Roussy ...
(Date:9/29/2014)... is here, and that means beer. And ... cold one, taking that first sip and ... reacted to form compounds that cause an ... why beers get skunky, and what you ... going bad. Learn all about it at ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3
... steps have public officials in your state or community taken ... who are obese has tripled in just 35 years. Local ... it either easy or hard for families to find fresh ... and be physically active. LOCAL GOVERNMENT ACTIONS TO PREVENT CHILDHOOD ...
... at Virginia Tech, Harvard and Drexel finish studying the locomotion ... has a few new ways to increase his own world-breaking ... to maneuver in tight places, or to hover in one ... has researchers wondering if they can create smarter materials that ...
... Zurich, Switzerland, August 18, 2009 / b3c newswire ... that, following the successful completion of key research ... disease has advanced into preclinical development, triggering milestone ... (NASDAQ: BIIB). Neurimmune partnered with Biogen Idec for ...
Cached Biology News:Tackling childhood obesity at the local level -- IOM report releases Sept. 1 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 3Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 2Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 3
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
... micro test tubes are used to store ... tubes have uniform walls for uniform heat ... O-ring screw caps. The O-rings are made ... operating range from -55 to 150 degrees ...
... Sac-Cel (Second Antibody Coated CELlulose) was ... Diagnostics of Dartford, Kent, one of the ... world. IDS acquired the product range in ... and clinical biochemists developing their own "in ...
Determine relative degree of protein binding to phosphoinositides...
Biology Products: